Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy.

Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy. Despite the results, Lilly plans to seek global approval, highlighting the pill's potential for convenience and its heart health benefits.

Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the drug for approval from the Food and Drug Administration.